Diazyme uses its proprietary enzyme technologies to develop diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme's products include test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes.
Diazyme Laboratories is a Division of General Atomics located in Poway, California and is a cGMP and ISO 13485 certified medical device manufacturer.
Click here for a map of our location.
Chong Yuan, Ph.D. – Managing Director
Dr. Yuan, a leading enzymologist, is the managing director and co-founder of Diazyme Laboratories. He is the inventor of multiple U.S. patents covering Diazyme product technology.
Scientific Advisory Board
Members of the Diazyme Scientific Advisory Board are well known leaders in the
scientific research community and clinical practice.
Gordon Chang, M.D.
Dr. Chang has been practicing internal medicine and non-invasive cardiology in San Jose since 1977. He is well read and has a keen interest in biotechnology. Dr. Chang is a member of electrocardiogram and echocardiogram panels for Alexian Brothers Hospital (Regional Medical Center of San Jose). He is also a member of the medical committee for selecting new drugs into the hospital formulary.
Richard D. Kolodner, Ph.D.
Dr. Kolodner, a member of the National Academy of Sciences, is head of the Laboratory of Cancer Genetics at the Ludwig Institute for cancer research, San Diego Branch. Dr. Kolodner is a Professor, at the Department of Medicine and Department of Cellular and Molecular Medicine, and Member of the Cancer Center at the University of California, School of Medicine. Prior to moving to San Diego, he was a full Professor in the Department of Biological Chemistry at the Harvard Medical School and the Dana-Farber Cancer Institute. He served as Head of the Laboratory of Molecular Genetics and Head of the Laboratory of X-Ray Crystallography. He has also served a three-year term as Chair of the Division of Cellular and Molecular Biology at the Dana-Farber Cancer Institute.
Dr. Kolodner is an Associate Editor of both Cell and Cancer Research and serves on the editorial board of Cellular and Molecular Biology. Dr. Kolodner has authored or co-authored more than 170 scientific publications. Honors and awards include an American Cancer Society Junior Faculty Research Award, 1981; an American Cancer Society Faculty Research Award, 1984; a National Institutes of Health MERIT Award, 1992; a Sandoz Special Scientific Achievement Award, 1994, and the 1996 Charles S. Mott Prize from the General Motors Cancer Research Foundation. Dr. Kolodner was also named the Charles A. Dana Investigator at the Dana-Farber Cancer Institute in 1996.
Michael Melnick, Ph.D.
Dr. Melnick started his career in biotech as a Staff Scientist at New England Biolabs, then helped spin off the antibody company Cell Signaling Technology where he was VP of Business and Corporate Development. He has also worked in venture capital as a Venture Partner at CMEA Capital where he invested in life science, industrial biotech, and cleantech. Currently he is VP of Business Development at the antibody drug discovery company BioAtla. He has a B.S. and M.S. in Biological Sciences from Stanford University, and a Ph.D. in Genetics from Harvard University.